GlassScriptPhysician profile
Brandi A Mendonca
NPI 1306941869
$2,417.02
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,035 · 2020: $128 · 2021: $225 · 2022: $228 · 2023: $333 · 2024: $467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $801.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $800.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $383.08 | 2019-2024 | |
| Novo Nordisk INC | $294.80 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $278.21 | 2019-2024 | Airsupra |
| Lilly USA, LLC | $224.72 | 2020-2024 | Jardiance, Mounjaro, Emgality |
| Amgen INC. | $183.08 | 2019-2022 | |
| Pfizer INC. | $127.91 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $89.82 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $86.88 | 2019 | |
| Glaxosmithkline, LLC. | $85.18 | 2019-2024 | Trelegy Ellipta, Shingrix, Pediarix |
| E.R. Squibb & Sons, L.L.C. | $82.05 | 2019-2023 | Camzyos |
| Otsuka America Pharmaceutical, INC. | $57.98 | 2019-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $54.89 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $54.09 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $51.92 | 2020-2021 | |
| Astellas Pharma US INC | $48.54 | 2019-2023 | Veozah |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $45.27 | 2021 | |
| Abbott Laboratories | $32.95 | 2022-2024 | Freestyle Libre 3 |
| Philips North America LLC | $32.42 | 2019 | |
| Amneal Pharmaceuticals LLC | $29.92 | 2024 | Ongentys, Rytary |
| Sanofi Pasteur INC. | $24.58 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.29 | 2024 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.66 | 2024 | Jardiance |
| Phadia US INC. | $16.25 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.49 | 2019 | |
| Janssen Biotech, INC. | $15.23 | 2019 | |
| Dexcom, INC. | $14.33 | 2019 | |
| Collegium Pharmaceutical, INC. | $13.50 | 2019 | |
| Boston Scientific Corporation | $13.47 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandi Mendonca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.